ArticlebioRxiv : the preprint server for biology2025
A Bayesian Informative Shrinkage Approach for Large-scale Multiple Hypothesis Testing (BISHOT): with Applications in Differential Analysis of Omics Data.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A major goal of many omics studies is to identify differential features, e.g. differentially expressed genes, between experimental groups. When performing differential analysis for a given dataset, relevant information from another platform or species is often available. Incorporating such prior information can help identify features that show consistent differential patterns across platforms or species, which are more likely to reflect shared biological processes, and thereby enhance the robustness and generalizability of the findings. However, existing differential analysis methods typically analyze only the data from the current study and do not leverage prior knowledge about the magnitude or direction of changes from other platforms or species. We address this challenge, and the associated multiple testing problem, using a Bayesian framework that enables the incorporation of prior knowledge obtained from different platforms or species. We propose a new test statistic, Bayesian Credible Ratio (BCR), based on a heteroscedastic global local shrinkage prior, and a new multiple testing criterion, sign-adjusted FDR (SFDR), that emphasize information regarding the direction of the differentially features. We prove that BCR achieves the largest count of sign-based true positives among all legitimate SFDR-controlling methods. Simulation results offer numerical evidence of its advantage compared to an empirical Bayesian method. The approach is demonstrated through the analysis of RNAseq and single-cell RNAseq datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.